User login
Key clinical point: Addition of panitumumab (Pmab) to fluorouracil/folinic acid (FU/FA) maintenance therapy significantly prolonged progression-free survival (PFS) compared with FU/FA alone in patients with RAS wild-type metastatic colorectal cancer (mCRC).
Major finding: The trial achieved its primary endpoint with a significant improvement in PFS with the addition of Pmab to FU/FA vs. only FU/FA maintenance therapy (8.8 months vs. 5.7 months; hazard ratio [HR], 0.72; P = .014). The most frequent grade 3 or more adverse event during maintenance in the Pmab arm was acneiform rash (7.2%).
Study details: PANAMA, a phase 2 trial included 377 patients with RAS wild-type mCRC who received induction therapy with 6 cycles of FOLFOX+Pmab. Patients with stable disease, partial or complete remission after induction, were randomly assigned to FU/FA+Pmab (n=125) or only FU/FA (n=123) maintenance therapy.
Disclosures: This trial was funded by AIO Studien gGmbH, Berlin, Germany, and Amgen. The authors declared receiving honoraria, research funding, travel and accommodation expenses, and/or consulting/advisory roles from various sources including Amgen.
Source: Modest DP et al. J Clin Oncol. 2021 Sep 17. doi: 10.1200/JCO.21.01332.
Key clinical point: Addition of panitumumab (Pmab) to fluorouracil/folinic acid (FU/FA) maintenance therapy significantly prolonged progression-free survival (PFS) compared with FU/FA alone in patients with RAS wild-type metastatic colorectal cancer (mCRC).
Major finding: The trial achieved its primary endpoint with a significant improvement in PFS with the addition of Pmab to FU/FA vs. only FU/FA maintenance therapy (8.8 months vs. 5.7 months; hazard ratio [HR], 0.72; P = .014). The most frequent grade 3 or more adverse event during maintenance in the Pmab arm was acneiform rash (7.2%).
Study details: PANAMA, a phase 2 trial included 377 patients with RAS wild-type mCRC who received induction therapy with 6 cycles of FOLFOX+Pmab. Patients with stable disease, partial or complete remission after induction, were randomly assigned to FU/FA+Pmab (n=125) or only FU/FA (n=123) maintenance therapy.
Disclosures: This trial was funded by AIO Studien gGmbH, Berlin, Germany, and Amgen. The authors declared receiving honoraria, research funding, travel and accommodation expenses, and/or consulting/advisory roles from various sources including Amgen.
Source: Modest DP et al. J Clin Oncol. 2021 Sep 17. doi: 10.1200/JCO.21.01332.
Key clinical point: Addition of panitumumab (Pmab) to fluorouracil/folinic acid (FU/FA) maintenance therapy significantly prolonged progression-free survival (PFS) compared with FU/FA alone in patients with RAS wild-type metastatic colorectal cancer (mCRC).
Major finding: The trial achieved its primary endpoint with a significant improvement in PFS with the addition of Pmab to FU/FA vs. only FU/FA maintenance therapy (8.8 months vs. 5.7 months; hazard ratio [HR], 0.72; P = .014). The most frequent grade 3 or more adverse event during maintenance in the Pmab arm was acneiform rash (7.2%).
Study details: PANAMA, a phase 2 trial included 377 patients with RAS wild-type mCRC who received induction therapy with 6 cycles of FOLFOX+Pmab. Patients with stable disease, partial or complete remission after induction, were randomly assigned to FU/FA+Pmab (n=125) or only FU/FA (n=123) maintenance therapy.
Disclosures: This trial was funded by AIO Studien gGmbH, Berlin, Germany, and Amgen. The authors declared receiving honoraria, research funding, travel and accommodation expenses, and/or consulting/advisory roles from various sources including Amgen.
Source: Modest DP et al. J Clin Oncol. 2021 Sep 17. doi: 10.1200/JCO.21.01332.